Skip to content
Bending the Curve Trial by Trial
?

Back to Non-Hodgkin lymphoma (DLBCL and follicular)

References: Non-Hodgkin lymphoma (DLBCL and follicular)

108 sources cited on this page. Links open the primary source.

  1. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38(4):1484-93. PubMedDOI
    CiteLoading…
  2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002-6. PubMedDOI
    CiteLoading…
  3. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-94. PubMedDOI
    CiteLoading…
  4. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540-5. PubMedDOI
    CiteLoading…
  5. US FDA, Center for Biologics Evaluation and Research. Approval letter to Genentech, Inc. for Rituximab (Rituxan), Our Reference No. 97-0244, 26 November 1997. Source
  6. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood. 1998;92(10):3562-8. PubMed
    CiteLoading…
  7. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-33. PubMedDOI
    CiteLoading…
  8. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-11. PubMedDOI
    CiteLoading…
  9. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-42. PubMedDOI
    CiteLoading…
  10. Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516-22. PubMedDOI
    CiteLoading…
  11. ClinicalTrials.gov. NCT00137995 (CORAL). Registry record, accessed 20 October 2026. NCT00137995
  12. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-91. PubMedDOI
    CiteLoading…
  13. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040-5. PubMedDOI
    CiteLoading…
  14. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-90. PubMedDOI
    CiteLoading…
  15. Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013-22. PubMedDOI
    CiteLoading…
  16. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42-51. PubMedDOI
    CiteLoading…
  17. Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30(36):4462-9. PubMedDOI
    CiteLoading…
  18. Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817-26. PubMedDOI
    CiteLoading…
  19. Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013;14(6):525-33. PubMedDOI
    CiteLoading…
  20. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-10. PubMedDOI
    CiteLoading…
  21. Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424-35. PubMedDOI
    CiteLoading…
  22. US FDA. Accelerated approval letter, Zydelig (idelalisib), NDA 205858 (relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic lymphoma), signed 23 July 2014. Source
  23. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944-52. PubMedDOI
    CiteLoading…
  24. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008-18. PubMedDOI
    CiteLoading…
  25. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. PubMedDOI
    CiteLoading…
  26. Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, et al. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2017;35(35):3898-3905. PubMedDOI
    CiteLoading…
  27. US FDA. Replacement accelerated approval letter, Aliqopa (copanlisib), NDA 209936 (relapsed follicular lymphoma after at least two prior systemic therapies); effective approval date 14 September 2017. Source
  28. US FDA. Supplement approval letter, Gazyva (obinutuzumab), BLA 125486/S-017 and S-018, signed 16 November 2017 (previously untreated stage II bulky, III or IV follicular lymphoma). Source
  29. FDA. Approval letter, BL 125643/0 (Yescarta, axicabtagene ciloleucel), 18 October 2017. Source
  30. Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377(14):1331-1344. PubMedDOI
    CiteLoading…
  31. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531-2544. PubMedDOI
    CiteLoading…
  32. US FDA. Accelerated approval letter, Copiktra (duvelisib), NDA 211155/Original 1 (relapsed or refractory follicular lymphoma after at least two prior systemic therapies), signed 24 September 2018. Source
  33. FDA. Supplement approval letter, BL 125646/76 (Kymriah, tisagenlecleucel; large B-cell lymphoma), 1 May 2018. Source
  34. Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N Engl J Med. 2018;379(10):934-947. PubMedDOI
    CiteLoading…
  35. Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-1799. PubMedDOI
    CiteLoading…
  36. FDA. Accelerated approval letter, BLA 761121 (Polivy, polatuzumab vedotin-piiq), electronic signature 10 June 2019. Source
  37. FDA. Supplement approval letter, NDA 021880/S-057 (Revlimid, lenalidomide), electronic signature 28 May 2019: addition of previously treated follicular lymphoma and previously treated marginal zone lymphoma, each in combination with a rituximab product. Text extracted and read 21 October 2026. Source
  38. Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, et al. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. J Clin Oncol. 2019;37(12):984-991. PubMedDOI
    CiteLoading…
  39. Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, et al. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. J Clin Oncol. 2019;37(11):912-922. PubMedDOI
    CiteLoading…
  40. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56. PubMedDOI
    CiteLoading…
  41. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-852. PubMedDOI
    CiteLoading…
  42. FDA, Center for Drug Evaluation and Research. Accelerated approval letter, BLA 761163 (Monjuvi, tafasitamab-cxix), signed 31 July 2020. Text extracted and read 21 October 2026. Source
  43. Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38(2):155-165. PubMedDOI
    CiteLoading…
  44. FDA. Approval letter, BL 125714/0 (Breyanzi, lisocabtagene maraleucel), 5 February 2021. Source
  45. US FDA. Replacement supplement approval letter dated 2 April 2021, Yescarta (axicabtagene ciloleucel), BL 125643/248 (relapsed or refractory follicular lymphoma, accelerated approval); effective approval date stated as 5 March 2021. Source
  46. FDA, Center for Drug Evaluation and Research. Accelerated approval letter, BLA 761196 (Zynlonta, loncastuximab tesirine-lpyl), signed 23 April 2021. Text extracted and read 21 October 2026. Source
  47. Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, et al. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2021;39(15):1609-1618. PubMedDOI
    CiteLoading…
  48. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021;5(20):4149-4155. PubMedDOI
    CiteLoading…
  49. Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2022;386(7):629-639. PubMedDOI
    CiteLoading…
  50. Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055-1065. PubMedDOI
    CiteLoading…
  51. Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;387(24):2220-2231. PubMedDOI
    CiteLoading…
  52. FDA. Supplement approval letter, BL 125714/90 (Breyanzi, lisocabtagene maraleucel; large B-cell lymphoma, two new indications), 24 June 2022. Source
  53. US FDA. Supplement approval letter, 27 May 2022, Kymriah (tisagenlecleucel), BL 125646/663 (relapsed or refractory follicular lymphoma, accelerated approval). Source
  54. US FDA. Accelerated approval letter, Lunsumio (mosunetuzumab-axgb), BLA 761263 (relapsed or refractory follicular lymphoma after two or more lines of systemic therapy), signed 22 December 2022. Source
  55. US FDA. Drug Safety Communication of 1 June 2022: FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns. Source
  56. FDA. Supplement approval letter, BL 125643/394 (Yescarta, axicabtagene ciloleucel; second-line large B-cell lymphoma), 1 April 2022. Source
  57. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325-332. PubMedDOI
    CiteLoading…
  58. Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91-103. PubMedDOI
    CiteLoading…
  59. Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294-2308. PubMedDOI
    CiteLoading…
  60. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386(7):640-654. PubMedDOI
    CiteLoading…
  61. Morschhauser F, Nastoupil L, Feugier P, Schiano de Colella JM, Tilly H, Palomba ML, et al. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma. J Clin Oncol. 2022;40(28):3239-3245. PubMedDOI
    CiteLoading…
  62. Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;386(4):351-363. PubMedDOI
    CiteLoading…
  63. National Library of Medicine, DailyMed. REVLIMID (lenalidomide) capsule, Celgene Corporation: structured product label, set ID 5fa97bf5-28a2-48f1-8955-f56012d296be, version 41 (effective 24 March 2023 as printed in the label file; the DailyMed list shows publication on 6 August 2026). Indications section read 21 October 2026. Source
  64. FDA. Accelerated approval letter, BLA 761309 (Columvi, glofitamab-gxbm), electronic signature 15 June 2023. Source
  65. FDA. Accelerated approval letter, BLA 761324 (Epkinly, epcoritamab-bysp), electronic signature 19 May 2023. Source
  66. US Food and Drug Administration. Supplement approval letter, BLA 761121/S-008, POLIVY (polatuzumab vedotin-piiq), Genentech, Inc.; electronic signature dated 19 April 2023. Drugs@FDA. Source
  67. Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1). Blood. 2023;141(19):2307-2315. PubMedDOI
    CiteLoading…
  68. Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023;41(12):2238-2247. PubMedDOI
    CiteLoading…
  69. Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023;389(2):148-157. PubMedDOI
    CiteLoading…
  70. US FDA. Supplement accelerated approval letter, 15 May 2024, Breyanzi (lisocabtagene maraleucel), BL 125714/225 (relapsed or refractory follicular lymphoma after two or more prior lines). Source
  71. US FDA. Accelerated approval letter, Epkinly (epcoritamab-bysp), BLA 761324/S-003 (relapsed or refractory follicular lymphoma after two or more lines of systemic therapy), signed 26 June 2024. Source
  72. Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11(8):e593-e605. PubMedDOI
    CiteLoading…
  73. Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143(6):496-506. PubMedDOI
    CiteLoading…
  74. Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024;38(12):2653-2662. PubMedDOI
    CiteLoading…
  75. National Library of Medicine, DailyMed. RITUXAN (rituximab) injection, solution, Genentech, Inc.: structured product label, set ID b172773b-3905-4a1c-ad95-bab4b6126563, version 36 (effective 6 January 2025). Indications section read 21 October 2026. Source
  76. Eyre TA, Cwynarski K, d'Amore F, de Leval L, Dreyling M, Eichenauer DA, et al. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(11):1263-1284. PubMedDOI
    CiteLoading…
  77. FDA. FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma. Announcement dated 11 February 2025. Page read 21 October 2026. Source
  78. US FDA. Supplement approval letter, Epkinly (epcoritamab-bysp), BLA 761324/S-009 (new indication with lenalidomide and rituximab; conversion to traditional approval of single-agent Epkinly in follicular lymphoma), signed 18 November 2025. Source
  79. FDA. Supplement approval letter, BLA 761163/S-013 (Monjuvi, tafasitamab-cxix), signed 18 June 2025: new indication in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. Text extracted and read 21 October 2026; the letter contains no accelerated-approval wording. Source
  80. Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. J Clin Oncol. 2025;43(24):2671-2678. PubMedDOI
    CiteLoading…
  81. Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trněný M, et al. Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2025;43(35):3698-3705. PubMedDOI
    CiteLoading…
  82. Cancer Research UK. Survival for non-Hodgkin lymphoma. Patient information page, last reviewed 9 May 2024 (next review due 9 May 2027) as printed on the page. Accessed 21 October 2026. Source
  83. ClinicalTrials.gov. NCT00064116 (MInT). Registry record, accessed 20 October 2026. NCT00064116
  84. ClinicalTrials.gov. NCT00144755 (LNH03-6B). Registry record, accessed 20 October 2026. NCT00144755
  85. ClinicalTrials.gov. NCT03274492 (POLARIX). Registry record, accessed 20 October 2026. NCT03274492
  86. ClinicalTrials.gov. NCT04529772 (ESCALADE). Registry record, API v2, accessed 20 October 2026 and checked again 21 October 2026. NCT04529772
  87. ClinicalTrials.gov. NCT05578976 (EPCORE DLBCL-2). Registry record, API v2, accessed 20 October 2026 and checked again 21 October 2026. NCT05578976
  88. ClinicalTrials.gov. NCT05605899 (ZUMA-23). Registry record, API v2, accessed 20 October 2026 and checked again 21 October 2026. NCT05605899
  89. ClinicalTrials.gov. NCT06047080 (SKYGLO). Registry record, API v2, accessed 20 October 2026 and checked again 21 October 2026. NCT06047080
  90. ClinicalTrials.gov. NCT06191744 (EPCORE FL-2). Registry record, API v2, accessed 20 October 2026 and checked again 21 October 2026. NCT06191744
  91. ClinicalTrials.gov. NCT06284122 (MorningLyte). Registry record, API v2, accessed 20 October 2026 and checked again 21 October 2026. NCT06284122
  92. DailyMed. Columvi (glofitamab) prescribing information, set ID 3516e753-f064-4d30-9bd5-e3f2e143f75d, label effective 25 June 2026 (accessed 20 October 2026). Source
  93. DailyMed. Epkinly (epcoritamab-bysp) prescribing information, set ID d7836711-b677-412d-bf2d-0f7c8444103a, label effective 22 June 2026 (accessed 20 October 2026). Source
  94. National Library of Medicine, DailyMed. GAZYVA (obinutuzumab) injection, solution, concentrate, Genentech, Inc.: structured product label, set ID df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda, version 23 (effective 1 October 2026). Indications section read 21 October 2026. Source
  95. European Medicines Agency. Columvi: EPAR summary page (page last updated 20 October 2026; accessed 21 October 2026). Source
  96. EMA. Lunsumio (mosunetuzumab): EPAR product page (accessed 21 October 2026; page last updated 7 October 2026): opinion adopted 22 April 2022, marketing authorisation issued 3 June 2022, conditional marketing authorisation. Source
  97. European Medicines Agency. Polivy: EPAR summary page (page last updated 20 October 2026; accessed 21 October 2026). Source
  98. European Medicines Agency. Tepkinly: EPAR summary page (page last updated 6 August 2026; accessed 21 October 2026). Source
  99. Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, et al. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. Lancet. 2026;407(10524):161-173. PubMedDOI
    CiteLoading…
  100. US FDA. Supplement approval letter, 20 February 2026, Breyanzi (lisocabtagene maraleucel), BL 125714/703 (accelerated approval required study fulfilled; conversion to traditional approval in follicular lymphoma). Source
  101. FDA. Ongoing | Cancer Accelerated Approvals. Listing, content current as of 19 October 2026 (accessed 20 October 2026). Source
  102. US Food and Drug Administration. Verified Clinical Benefit | Cancer Accelerated Approvals. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. Content current as of 16 October 2026. Source
  103. FDA. Withdrawn | Cancer Accelerated Approvals. Listing, content current as of 5 October 2026 (accessed 19 October 2026). Source
  104. Lenz G, Trněný M, Burke JM, Nowakowski GS, Fox CP, Chiappella A, et al. Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10547):2528-2541. PubMedDOI
    CiteLoading…
  105. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: NHL - Diffuse Large B-Cell Lymphoma (DLBCL). Page accessed 20 and 21 October 2026; the page displays no update date (its HTTP Last-Modified header read 22 April 2026). Source
  106. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Follicular Lymphoma. Page accessed 20 and 21 October 2026; the page displays no update date (its HTTP Last-Modified header read 22 April 2026). Source
  107. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Non-Hodgkin Lymphoma. Page accessed 20 and 21 October 2026; the page displays no update date (its HTTP Last-Modified header read 22 April 2026). Source
  108. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Altahan A, Andreadis B, et al. B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026;24(9). PubMedDOI